The COVID-19 pandemic brought life-changing disruptions to people around the world and has turned the typical vaccine R&D process on its head. A combination of urgent need, unprecedented investments, and advances in genetic engineering has allowed what was once mere speculation to become not only our reality, but our future.

With pandemic vaccines now launching at record speeds, the first Genetic Vaccine Development for Infectious Diseases Summit will focus on overcoming the translational and clinical challenges of developing genetic vaccines targeting infectious diseases, including Influenza, Lassa fever, Ebola, MERS, HIV, Zika, and COVID-19.

With a focus on mRNA, DNA, and engineered viral vector-based vaccines, this niche 3-day agenda has been specifically designed to help industry experts to discuss new genetic-based vaccine platforms, preclinical and clinical case studies, optimized delivery methods, and the future of vaccine R&D to usher in a new era of vaccinology, with experts from BioNTech, Pfizer, Moderna, AstraZeneca and CureVac.

To know more about Genetic Vaccine Development for Infectious Diseases Summit please
click here.